February 25: The Week in Cancer News
Screening program reduces disparities in colorectal cancer, and seeing the challenges of getting cancer care through one woman’s story.
Progress Against Cancer
Screening program reduces disparities in colorectal cancer, and seeing the challenges of getting cancer care through one woman’s story.
Aspirin is ineffective in preventing breast cancer recurrence, and immunotherapy holds promise for some patients with advanced anal cancer.
A new report from the American Association for Cancer Research explores how the COVID-19 pandemic affected cancer patients, researchers and care providers.
Editor’s note: This story, written by Anna Azvolinsky, first appeared in Leading Discoveries, a magazine and website that raises awareness of the AACR and its members. To learn more about Dr. Carpten’s involvement with AACR...
Millions miss cancer screenings, and commercial tobacco ban goes into effect for Navajo Nation after years of failed attempts.
The COVID-19 pandemic has taken a devastating toll, with 5.8 million deaths worldwide, including nearly 1 million in the United States alone. The pandemic’s effects have rippled through virtually every facet of life, shuttering...
Compared to urbanites, rural residents tend to think little can be done about cancer and feel overloaded with cancer-related information.
CAR T-cell therapy effects continue 10 years after treatment and first T-cell receptor therapeutic approved for uveal melanoma.
In the United States, advances in cancer research have dramatically improved outcomes for children diagnosed with cancer. While pediatric cancer remains a devastating diagnosis, approximately 80 percent of children survive their disease. For children...
Margaret Foti, PhD, MD (hc), chief executive officer of the American Association for Cancer Research (AACR), along with other AACR leaders, joined President Joseph R. Biden at a White House event Wednesday as he...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More